Department of Haematology and.
Hum Mol Genet. 2013 Nov 1;22(21):4329-38. doi: 10.1093/hmg/ddt282. Epub 2013 Jun 16.
We undertook a gene identification and molecular characterization project in a large kindred originally clinically diagnosed with SCA-X1. While presenting with ataxia, this kindred also had some unique peripheral nervous system features. The implicated region on the X chromosome was delineated using haplotyping. Large deletions and duplications were excluded by array comparative genomic hybridization. Exome sequencing was undertaken in two affected subjects. The single identified X chromosome candidate variant was then confirmed to co-segregate appropriately in all affected, carrier and unaffected family members by Sanger sequencing. The variant was confirmed to be novel by comparison with dbSNP, and filtering for a minor allele frequency of <1% in 1000 Genomes project, and was not present in the NHLBI Exome Sequencing Project or a local database at the BCM HGSC. Functional experiments on transfected cells were subsequently undertaken to assess the biological effect of the variant in vitro. The variant identified consisted of a previously unidentified non-synonymous variant, GJB1 p.P58S, in the Connexin 32/Gap Junction Beta 1 gene. Segregation studies with Sanger sequencing confirmed the presence of the variant in all affected individuals and one known carrier, and the absence of the variant in unaffected members. Functional studies confirmed that the p.P58S variant reduced the number and size of gap junction plaques, but the conductance of the gap junctions was unaffected. Two X-linked ataxias have been associated with genetic loci, with the first of these recently characterized at the molecular level. This represents the second kindred with molecular characterization of X-linked ataxia, and is the first instance of a previously unreported GJB1 mutation with a dominant and permanent ataxia phenotype, although different CNS deficits have previously been reported. This pedigree has also been relatively unique in its phenotype due to the presence of central and peripheral neural abnormalities. Other X-linked SCAs with unique features might therefore also potentially represent variable phenotypic expression of other known neurological entities.
我们在一个最初被临床诊断为 SCA-X1 的大型家族中进行了基因鉴定和分子特征项目。该家族在表现出共济失调的同时,还具有一些独特的周围神经系统特征。使用单体型作图法划定了 X 染色体上的涉及区域。通过阵列比较基因组杂交排除了大片段缺失和重复。对两个受影响的个体进行了外显子组测序。然后通过 Sanger 测序,在所有受影响、携带者和未受影响的家族成员中,对单个鉴定的 X 染色体候选变体进行了适当的共分离确认。通过与 dbSNP 比较,将变体过滤为 1000 Genomes 项目中频率 <1%的罕见等位基因,并在 NHLBI Exome Sequencing Project 或 BCM HGSC 的本地数据库中未发现变体,从而确认变体是新颖的。随后对转染细胞进行了功能实验,以评估变体在体外的生物学效应。鉴定出的变体由 Connexin 32/Gap Junction Beta 1 基因中的先前未识别的非同义变体 GJB1 p.P58S 组成。与 Sanger 测序的分离研究证实,该变体存在于所有受影响的个体和一个已知的携带者中,而在未受影响的成员中不存在该变体。功能研究证实,p.P58S 变体减少了缝隙连接斑块的数量和大小,但缝隙连接的电导率不受影响。已经有两种 X 连锁共济失调与遗传基因座相关,其中第一种最近已在分子水平上得到了表征。这是第二个具有分子特征的 X 连锁共济失调家族,也是第一个以前未报道的 GJB1 突变的显性和永久性共济失调表型的实例,尽管以前已经报道了不同的中枢神经系统缺陷。由于存在中枢和周围神经异常,该家系的表型也相对独特。因此,其他具有独特特征的 X 连锁 SCA 也可能代表其他已知神经实体的可变表型表达。